- Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity. Zhou, L., An, N., Haydon, R.C., Zhou, Q., Cheng, H., Peng, Y., Jiang, W., Luu, H.H., Vanichakarn, P., Szatkowski, J.P., Park, J.Y., Breyer, B., He, T.C. Cancer Lett. (2003)